Specialties
- Pheochromocytoma
- Paraganglioma
- Carcinoid Tumor
- Neuroendocrine Tumors
- Medical Oncology
Board Certification
|
American Board of Internal Medicine (Sub: Medical Oncology)
Educational Commission for Foreign Medical Graduates
|
Patient Rating
Patients consistently commend Dr. Soares for her deep expertise in neuroendocrine cancer and a thorough, well-prepared approach to care. Many say she listens attentively, explains diagnosis and treatment options clearly, and treats them with compassion and respect. Reviewers also praise her coordination with other specialists and note friendly, supportive staff that reinforce their confidence in the care provided.
Generated via Patient Reviews
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Professor (Clinical) Radiology & Imaging Sciences -Adjunct Professor |
|---|---|
| Academic Divisions |
Oncology
|
| Board Certification |
American Board of Internal Medicine (Sub: Medical Oncology)
Educational Commission for Foreign Medical Graduates
|
Selected Publications
Journal Article
- ORorke MA, Xu T, Decook RR, Mcdowell BD, Gryzlak BM, Rudzianski NJ, Serrano KC, Wehrheim AM, Grewal US, Chandrasekharan C, Dillon JS, Halfdanarson TR, Gamblin TC, Cowell LG, Else T, Soares HP, Sukrithan V, Chandaka S, Sanoff HK, He FC, Geller D, Ramirez RA, Liu M, Lancaster W, Mailman JA, Moran H, Wahmann M, Gellerman E, Chrischilles EA, NET-PRO Study Investigators (2026). Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohort. J Natl Cancer Inst.
- ORorke MA, Gryzlak BM, Xu T, McDowell BD, DeCook RR, Rudzianski NJ, Serrano KC, Wehrheim AM, Grewal US, Chandrasekharan C, Dillon JS, Halfdanarson TR, Schnell MJ, Witter CL, Gamblin TC, Kazmi S, Cowell LG, Else T, Soares HP, Sukrithan V, Chandaka S, Sanoff HK, He FC, Geller DA, Ramirez RA, Liu M, Lancaster W, Mailman JA, Moran H, Wahmann M, Gellerman E, Chrischilles EA (2026). Using a participation monitoring database to enhance recruitment in a rare cancer population. J Clin Transl Sci, 10(1), e40.
- Marks JA, Sweeney K, Elliott A, Gupta B, VanderWalde A, Puri S, Shields MD, Nieva JJ, Soares HP, Ma PC, Halmos B, Liu SV (2026). SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer. Lung Cancer, 213, 108913.
- Wheless MC, Stockton S, Soares HP, Dayyani F, Saeed A, Kim E, Jin N, Yacoub G, Florou V, Ayers GD, Guerrouahen BS, Contreras A, Li L, Ferry-Galow KV, Gore S, Das S, Berlin J (2025). NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer. Oncologist, 30(12).
- Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies Consortium Group (2024). Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer, 131(13), e35871.
- Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies PSM Consortium Group (2025). Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms. Ann Surg Oncol.
- Sukrithan V, Ahmed U, Krause H, Gandhi N, Elliott A, Hinton A, Walker P, Vanderwalde A, Zhou Y, Patel DC, Lou E, Soares HP, Rogers KA, Konda B (2025). Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms. Endocr Relat Cancer, 32(7).
- Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA, Kunz PL, Mailman J, Arshad J, Soares HP, Singh S, Chandrasekharan C, Soulen MC, Janson ET, Halfdanarson TR, Strosberg JR, Bergsland EK (2025). Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO Oncol Pract, OP2500133.
- Azar I, Khan HY, Bannoura SF, Gandhi N, Uddin MH, Nagasaka M, Gong J, Nazha B, Choucair K, Vojjala N, Khushman MM, Soares HP, El-Deiry WS, Philip PA, El-Rayes B, Chen H, Lou E, Muqbil I, Farrell AP, Swensen J, Oberley MJ, Nabhan C, Goel S, Shields AF, Mohammad RM, Pasche BC, Azmi AS (2025). Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations. JCO Oncol Adv, 2(1), e2400032.
- Lozada JR, Elliott A, Evans MG, Wacker J, Storey KM, Egusa EA, Zorko NA, Kumar A, Crymes A, Heath EI, Carneiro BA, Soares HP, Cichocki F, Miller JS, Lou E, Beltran H, Antonarakis ES, Ryan CJ, Hwang JH (2024). Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting. Cancer Res Commun, 5(2), 318-326.
- Norton C, Shaw MS, Rubnitz Z, Smith J, Soares HP, Nevala-Plagemann CD, Garrido-Laguna I, Florou V (2025). KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA Netw Open, 8(1), e2453588.
- Sahai V, Griffith KA, Lin BS, Soares HP, Chandana SR, Crysler O, Kumar-Sinha C, Enzler T, Dippman D, Gunchick V, Zalupski MM (2024). BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer. Med, 100547.
- Xue E, Bracken-Clarke D, Krause H, Adeyelu T, Evans MG, Akbulut D, Quezado M, Gandhi N, Farrell A, Soares HP, Lou E, Phan M, Patel R, Vanderwalde AM, Elliott A, Steuer CE, Saba NF, Lubin DJ, London NR Jr, Gulley JL, Floudas CS (2024). Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies. Cancers (Basel), 16(23).
- Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, Kelkar AH, Law LY, LeFebvre KB, Ljungman P, Miller ED, Meyer LA, Moore HN, Soares HP, Taplitz RA, Woldetsadik ES, Kohn EC (2024). Vaccination of Adults With Cancer: ASCO Guideline. J Clin Oncol, 42(14), 1699-1721.
- ORorke M, Chrischilles E, NETPRO Study Investigators (2024). Making progress against rare cancers: A case study on neuroendocrine tumors. Cancer, 130(9), 1568-1574.
- Wilbur HC, Soares HP, Azad NS (2024). Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations. Hepatology.
- Mosley SA, Cicali E, Del Cueto A, Portman DG, Donovan KA, Gong Y, Langaee T, Gopalan P, Schmit J, Starr JS, Silver N, Chang YD, Rajasekhara S, Smith JE, Soares HP, Clare-Salzler M, Starostik P, George TJ, McLeod HL, Fillingim RB, Hicks JK, Cavallari LH (2023). CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial. Pharmacotherapy, 43(12), 1286-1296.
- Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK (2023). Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol, 41(32), 5049-5067.
- Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, NET CTPM participants (2022). Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst, 115(9), 1001-1010.
- Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417.
- Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Front Immunol, 14, 1229823.
- Leiter RE, Varas MTB, Miralda K, Muneton-Castano Y, Furtado G, Revette A, Cronin C, Soares HP, Lopez A, Hayman LL, Lindsay AC, Schrag D, Enzinger AC (2023). Adaptation of a Multimedia Chemotherapy Educational Intervention for Latinos: Letting Patient Narratives Speak for Themselves. J Cancer Educ, 38(4), 1353-1362.
- Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer, 11(8).
- Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA (2023). Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer, 30(8).
- Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao R (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. J Gastrointest Cancer, 54(2), 492-500.
- Okwundu N, Weil CR, Soares HP, Fine GC, Cannon DM (2023). Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases. Front Nucl Med, 3, 1074948.
- Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C (2021). Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(7), 839-868.
- Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC, from the Carcinoid Syndrome Control Collaborative (2020). Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas, 49(9), 1123-1130.
- Kim R, Sanoff H, Poklepovic A, Soares H, Kim J, Lyu J, Liu Y, Kim D (2020). A multi-institutional phase II trial of regorafenib in refractory advanced biliary tract cancer. Accepted. . Cancer.
- Al-Toubah T, Schell MJ, Cives M, Zhou JM, Soares HP, Strosberg JR (2019). A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology, 110(5), 377-383.
- Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP (2019). Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol, 10(4), 647-687.
- Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R (2018). Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs, 37(3), 473-481.
- Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK (2019). Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol, 37(12), 1015-1027.
- Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH (2018). Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp Clin Trials, 68, 7-13.
- Cives M, Anaya DA, Soares H, Coppola D, Strosberg J (2017). Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors. J Natl Cancer Inst, 110(3), 282-289.
- Wainberg ZA, Alsina M, Soares HP, Braa I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J (2017). A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol, 12(6), 775-785.
- Cives M, Soares HP, Strosberg J (2016). Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol, 28(4), 359-66.
- Wainberg ZA, Soares HP, Patel R, DiCarlo B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, Brennan M, Hecht JR (2015). Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers. Cancer Chemother Pharmacol, 76(1), 61-7.
- Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt E (2015). Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Mol Cancer Ther, 14(4), 1014-23.
- Ming M, Sinnett-Smith J, Wang J, Soares HP, Young SH, Eibl G, Rozengurt E (2014). Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS One, 9(12), e114573.
- Rozengurt E, Soares HP, Sinnet-Smith J (2014). Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther, 13(11), 2477-88.
- Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM (2014). A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol, 73(4), 839-45.
- Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E (2013). Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One, 8(2), e57289.
- Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers I (2012). New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev, 10, MR000024.
- Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A (2012). Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol, 65(6), 602-9.
- Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ (2010). Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol, 64(6), 583-93.
- Soares HP, Lutzky J (2010). Velimogene aliplasmid. Expert Opin Biol Ther, 10(5), 841-51.
- Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, STOPIT-2 Study Group, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schnemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T (2010). Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA, 303(12), 1180-7.
- Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, Schnemann H, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt GH (2009). Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials, 10, 49.
- Trufelli DC, Bensi CG, Garcia JB, Narahara JL, Abro MN, Diniz RW, Miranda Vda C, Soares HP, Del Giglio A (2008). Burnout in cancer professionals: a systematic review and meta-analysis. Eur J Cancer Care (Engl), 17(6), 524-31.
- Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL (2008). Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med, 168(6), 632-42.
- Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF (2008). Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med, 49(3), 480-508.
- Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G (2007). A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol, 2(12), 1091-7.
- Rocha-Lima CM, Soares HP, Raez LE, Singal R (2007). EGFR targeting of solid tumors. Cancer Control, 14(3), 295-304.
- Behera M, Kumar A, Soares HP, Sokol L, Djulbegovic B (2007). Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control, 14(2), 160-6.
- Kumar A, Soares HP, Balducci L, Djulbegovic B, National Cancer Institute (2007). Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol, 25(10), 1272-6.
- Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 33(1), 87-9.
- Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for lung cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(8), 652-5.
- Djulbegovic B, Soares HP, Kumar A (2006). What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treat Rev, 32(7), 572-6.
- Kumar A, Soares HP, Djulbegovic B (2006). Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(7), 577-80.
- Kumar A, Soares HP (2006). Salvage radiotherapy increases survival in people with residual disease after chemotherapy for advance diffuse large cell lymphoma. Cancer Treat Rev, 32(6), 487-90.
- Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B, Childrens Oncology Group (2005). Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ, 331(7528), 1295.
- Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B (2005). Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA, 293(8), 970-8.
- Kumar A, Soares H, Serdarevic F (2005). Totality of evidence: one of the keys to better oncology management. J Oncol Manag, 14(1), 12-4.
- Weinschenker P, Soares HP, Clark O, Del Giglio A (2004). Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat, 87(3), 215-24.
- Megale Costa LJ, Soares HP, Gaspar HA, Trujillo LG, Santi PX, Pereira RS, de Santana TL, Pinto FN, del Giglio A (2004). Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol, 27(3), 304-6.
- Samano ES, Goldenstein PT, Ribeiro Lde M, Lewin F, Filho ES, Soares HP, del Giglio A (2004). Praying correlates with higher quality of life: results from a survey on complementary/alternative medicine use among a group of Brazilian cancer patients. Sao Paulo Med J, 122(2), 60-3.
- Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B, Radiation Therapy Oncology Group (2004). Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ, 328(7430), 22-4.
- Fonseca FL, Soares HP, Manhani AR, Bendit I, Novaes M, Zatta SM, Arias V, Pinhal MA, Weinschenker P, del Giglio A (2002). Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy. Clin Breast Cancer, 3(3), 201-5.
- Pereira LP, Waisberg J, Andr EA, Zanoto A, Mendes Jnior JP, Soares HP (2002). Detection of Helicobacter pylori in gastric cancer. Arq Gastroenterol, 38(4), 240-6.
- Manhani AR, Manhani R, Soares HP, Bendit I, Lopes F, Nicoletti AG, Fonseca FL, Novaes M, Zatta SM, Arias V, Giralt S, del Giglio A (2001). CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. Breast Cancer Res Treat, 66(3), 249-54.
- del Giglio A, Soares HP, Caparroz C, Castro PC (2001). Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer, 89(11), 2301-8.
Review
- El-Haddad G, Gardner L, Kim H, Soares HP (2026). Occurrence and Management of Acute, Subacute, and Delayed Toxicities in Patients with GEP-NETs Following Treatment with Radioligand Therapy. [Review]. Cancers (Basel), 18(5).
- Scarini JF, Gonalves MWA, de Lima-Souza RA, Lavareze L, de Carvalho Kimura T, Yang CC, Altemani A, Mariano FV, Soares HP, Fillmore GC, Egal ESA (2024). Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets. [Review]. Front Oncol, 14, 1275330.
- Naraev BG, Mailman J, Halfdanarson TR, Soares HP, Mittra ES, Hallet J (2023). Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors. [Review]. Expert Rev Anticancer Ther, 23(6), 601-615.
- Chauhan A, Del Rivero J, Ramirez RA, Soares HP, Li D (2022). Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. [Review]. Cancers (Basel), 14(21).
- Jacob A, Raj R, Allison DB, Soares HP, Chauhan A (2022). An Update on the Management of Mixed Neuroendocrine-Non-neuroendocrine Neoplasms (MiNEN). [Review]. Curr Treat Options Oncol, 23(5), 721-735.
- Egal ESA, Jacenik D, Soares HP, Beswick EJ (2021). Translational challenges in pancreatic neuroendocrine tumor immunotherapy. [Review]. Biochim Biophys Acta Rev Cancer, 1876(2), 188640.
- Hunter LA, Soares HP (2021). Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. [Review]. Cancers (Basel), 13(20).
- Nemunaitis JM, Brown-Glabeman U, Soares H, Belmonte J, Liem B, Nir I, Phuoc V, Gullapalli RR (2018). Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. [Review]. BMC Cancer, 18(1), 665.
Book Chapter
- Soares HP, Strosberg J (2016). Targeted Therapies for Neuroendocrine Neoplasms. In Nasir A, Coppola D (Eds.), Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. Springer.
- Soares HP, Kumar A, Bennett C, Djulbegovic B (2008). The Role of Hematopoietic Growth Factors in Managing Patients with Hematologic Malignancies. In Crowther MA, Ginsberg J, Schunemann H, et al (Eds.), Evidence-based Hematology (pp. 402-12). West Sussex, United Kingdom: BMJ Books.
Editorial
- Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR (2020). North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas, 49(6), 723-728.
Letter
- Ryan CE, Saif A, Rocha F, Philip P, Hernandez JM, Ahmad S, Soares H (2022). Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors. [Letter to the editor]. Ann Surg Oncol, 30(3), 1302-1304.
Other
- Loaiza-Bonilla A, Benson AB 3rd, Grothey A, Karimi M, Klempner SJ, Lin D, Mahtani R, Soares HP (2021). Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. Oncologist (26(8), pp. 651-659). England.
News & Podcasts
News
Huntsman Cancer Institute News
- Discovery Innovations Summer 2026
- Talks with Docs: Heloisa Soares, MD, PhD
- Highlights of Huntsman Cancer Institute Awards and Appointments Spring 2026
- First Three Patients Treated with Novel Theranostics Drug in First-in-Human Clinical Trial
- Finding Hope in Theranostics
- Leaders Drive Theranostics Expansion to Transform Cancer Care
- What Is Preventative Chemotherapy and How Does It Work?
- Ricky’s Ride with Neuroendocrine Pancreatic Cancer
- Ask an Expert: The Truth About Clinical Trials
- Building on the Lifesaving Work of Cancer Research
- Researcher Receives Awards for Community Contributions and Neuroendocrine Tumor Research
Dr Soares takes the time to explain the process and seems to care about me as an individual making me feel comfortable.
Dr Soares & her team are amazing.
She is very thorough and caring
Dr. Soares is great. I have been under her care for 5 years, and she is always well prepared for my visits and explains the next steps in my care plan.
Always understanding and personally assures that one is taking care of.
Doctor Soares is very knowledgeable and kind. She helped me get the answers to questions I needed answers for . She has made a plan with steps in my treatment. I appreciate her caring and listening and clarifications of my conditon and care plan. I loved her sense of humor. Humor makes life and trials easier to endure. Thank you.
Doctor Soares is the best doctor we have experienced throughout this whole ordeal. She is very thorough, knowledgeable, collaborative, and caring. We completely trust.her medical advice and care. She is a true gem!
Very through
Dr. Soares is very knowledgeable about neuroendocrine tumors and all the different treatment options. She is also kind and compassionate.
I am confident in her abilities, very personable.
Dr. Soares in an expect in her NET specialty research and training. I feel very fortunate that she was recommended to me and I have complete confidence in her guidance in providing me the best treatment care possible that fits my specific needs and goals.
Dr Soares is caring and compassionate. She is very knowledgeable about neuroendocrine Cancer. She gave us hope when other doctors didn't. She cares about you personally. You are not just another patient. She coordinates with other doctors on other teams. I hope she never leaves Huntsman.
She looks at any problem and looks into it and notifies you the minute she has an answer.
Dr. Soares will help me to get the best results possible from the treatment she feels is right.
Caring person
Dr. Soares is an excellent Doctor who cares about you as a patient and person. I'm so blessed to have Dr. Soares as my Oncologist.
Dr Soares and her team have my health as their primary concern. I feel she truly listens and wants to provide the best care and options for me. She is very positive and realistic.
Year 3 with Dr Soares and her team. She knows me as a person, not just my cancer. She asks about my 94 year old dad. I trust her with my life.
She is the third doctor that I have had at that hospital. She seems to be the most caring one and keeps us up-to-date and answers any questions that I have
Very knowledgeable. Understands a patients point of view and is helpful in explaining what choices you have in your healthcare plan.
She is amazing and cares about me and my family and helped to get my husband in with his new Dr for his treatment Dr Florou. Dr Soares has turned my health around and I feel so much stronger and healthier. I can't began to even explain how much I appreciate her care Thank you
Excellent doctor
Dr. Soares is very professional and provides excellent care.
Dr. Soares is everything you could ever want in an excellent doctor. I'm truly blessed to have her as my oncologist.
Always listens and addresses my concerns. Friendly and understanding.
Kind, considerate, cares about her patients. Great clarity explaining results of workups and procedures.
I have received very good care by her and she listen to what I need.
Dr Soares knows what she is talking about and has great bedside manner. Her staff are courteous and sympathetic
Dr. Soares is fantastic! Kind, compassionate, caring, smart and great bedside manner.
She is very expert in the areas where I have problems. She was very nice and attentive to my needs.
Dr Soares was very informed and helpful regarding treatment of my advanced NET
I am grateful for Dr. Soares's in her personal expertise as well as her deep connection to other NET specialist around the country and across the globe. Her contributions to treating this caner are immense. I completely trust she and her NET colleagues to tailor my treatment to my unique needs and lifestyle.
She really cares about her patients.
Dr. Soares has always been very caring and professional when I see her. She explains everything so I understand what is going on.
She's excellent, and I look forward to seeing her each visit.
I fully trust Dr Soares she has provided the very best care and takes and addresses my needs as they arise with NETs she has given me hope that I didn't feel I had before seeing her as my Oncologist.
Totally trust Dr Soares decisions on my care, very knowledgeable about my specific disease.
Dr. Soares and her staff make sure youbare recieving the best care available.
Thorough professional and thoughtful care. Patient and complete explanations of questions and concerns. Highly recommend Dr. Soares to anyone seeking counsel and treatments.
Great Doctor!
I feel lucky having her as my provider!
Dr. Soares is highly knowledgeable, compassionate, and attentive. She takes the time to clearly explain her recommendations and considers your personal concerns to find the best care options tailored to you.
DR Soares is the most awesome doctor there is. Her care is over the top. Thank you. :-))
I literally trust her with my treatment....my life. She knows me as a person as well as my health issue. She is the BEST!
The Doctor was pleasant and wants more information such as a procedure at the university. I don't think she can answer many questions until she meets with a committee.
Thank you for directing my treatment. It is has been quite a journey and I would not be experiencing the well being I have today without your care.
Thoughtful, Prompt , Cheerful, Knowledgeable. Treats us like friends.
Dr. Soares is someone I don't mind placing my life in her decisions. Experiencing the way she made me feel important is the reason I don't mind the four hour drive for the visit.
She is an amazing caring doctor and is expert with NETs and puts me at ease I love her
Dr Soares is the best Dr. I have ever had. I am very confident in her capabilities.
Dr Soares is amazing! She has soft bedside manner and is very knowledgeable. However, she won't mince words and she'll come straight to the point when it's needed for optimal health care. I adore her.
Dr. Soares is an excellent Doctor who explains all possible ways to treat my cancer. She is very caring and has a great sense of humor. I trust Her implicitly!! Exceptional person and Doctor. ?????
Dr Soares was very informative and helpful with the telemedicine encounter. I feel very fortunate to have her expertise and guidance with my NET care.
Very caring respectful of her patients feelings
Dr. Soares is incredibly knowledgeable about neuroendocrine cancer and truly cares about her patients. She always comes prepared, having reviewed my scans and history, and takes the time to listen and ask thoughtful questions. I appreciate how kind, proactive, and dedicated she is to keeping me as healthy as possible. I feel very lucky to be in her care.
Excellent provider and communicator with my health issues.
After talking with my daughter who is a CRA I was amazed to find out that this doctor was thinking I was expecting a miracle. NO I'm very aware of what is going to happen and hope I beat her odds.
Dr Soares is the best and most knowledgeable medical professional I have ever had.
I immediately liked Dr. Soares, her seriousness and passion towards her work. In our meeting she conveyed an authentic manner and projected both warmth and empathy. She is an excellent listener giving you complete attention.
So thankful for her!
Fantastic Doctor I feel blessed to be under her care
Doctor Heloisa P Soares is very personal and professional. She has traeted me for several years. I would recommend her to anyone.
we are so pleased that we were referred to your clinic by another patient
She always brings a smile and lightens the room up and knows how to address situations in a positive manner.
Dr. Soares is an amazing doctor. She is very thorough and truly cares about her patients. I very much appreciate everything she has done to advocate for me and she continues to do so each time I see her.
Dr Soares cares about you individually. Not just about your Neuroendocrine Cancer. She also includes other specialties to help you have a better outcome. She works with my Nephrologist and Endocrinologist to make sure I can be as healthy as possible during my Cancer journey. She is good at Neuroendocrine Cancer and I wouldn't go to anyone else.
Dr. Soares is very knowledgeable and professional.
Dr. Soares is always pleasant and understanding. She takes the time to answer all my questions.
DR Soares and her staff are fantasic. Polite friendly, fun. We were put at ease and were impressed with their concern Dr Soares took time the explain everything and make sure we understood the issues. Excellent kind and caring
Amazing caring respectful great doctor
I was very pleased. She was is making sure all avenues are covered.
Dr. Soares is a wonderful provider. Her expertise is essential to my treatment. I have complete confidence in Dr. Soares and appreciate her caring demeanor. I feel she is good at patient led treatment in assessing what the best options are for me personally.
Exceptional care, treatment, and support. Dr. Soares is a professional physician who specializes in treating the patients with respect and dignity. I highly recommend Dr. Soares !!?????